Citrus Pathology Lab

We have created several transgenic lines expressing the Arabidopsis thaliana NPR1 (AtNPR1) gene, which have shown consistent and robust tolerance to Huanglongbing (HLB) through multiple generations of grafting-propagated progeny plants. Despite high levels of AtNPR1 protein in the leaves of these transgenic plants, minimal accumulation occurs in the fruit pulp and juice. Importantly, any residual AtNPR1 in the fruit can be rapidly broken down by digestive enzymes such as pepsin and trypsin in the stomach and intestines, ensuring that the transgenic citrus remains safe for consumption. Our primary objective here is to scale up production of these promising transgenic lines for large-scale field trials at two prominent locations in Florida. Concurrently, we will gather comprehensive data to support plant patent applications and secure regulatory approvals from USDA, EPA, and FDA. Furthermore, we will provide clean budwood resources to the industry through the FDACS/DPI Bureau of Citrus Budwood Registration Program, facilitating widespread adoption of these advanced transgenic citrus varieties. Addressing public concerns about genetically modified organisms (GMOs) is our secondary goal. To achieve this, we will conduct an extensive review of public attitudes and perceptions via literature analysis and environmental scans focused on genetic modification. This foundational research will guide a targeted survey designed to identify knowledge gaps and perceptions specifically related to transgenic citrus. Based on these insights, we will develop tailored communication tools and educational materials to effectively communicate the benefits and safety of AtNPR1 transgenic citrus to stakeholders, aiming to foster acceptance among

consumers and citrus growers alike.